V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240002597 | 240005248 | null | 15.75 | null | 2017-06-12 | 2017-06-13 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | null | CISPLATIN + GEMCITABINE | 101029319 |
| 240002598 | 240005249 | 0 | 30 | Curative (C) | null | 2017-11-18 | null | Y | N | TRIAL | 101400535 |
| 240002604 | 240005253 | 1.78 | 62 | null | 2016-09-23 | 2016-09-24 | DA | 02 | null | CARFILZOMIB | 100898534 |
| 240002605 | 240005254 | 1.75 | 54.9 | null | 2016-01-28 | 2016-02-02 | BENDAMUSTINE | 02 | null | NOT MATCHED | 101333931 |
| 240002606 | 240005255 | 0 | 0 | null | 2016-12-05 | 2016-12-12 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | null | ANAGRELIDE | 100147441 |
| 240002607 | 240005256 | 0 | 70 | null | null | 2017-09-14 | null | null | null | AML16 TRIAL | 100139463 |
| 240002608 | 240005257 | 1.7 | 110.5 | Adjuvant (A) | null | 2017-07-15 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | N | N | BUSULFAN | 101185786 |
| 240002609 | 240005258 | 1.6 | 49 | null | 2019-11-03 | 2019-11-03 | ALL UKALL2011 Consolidation A | 02 | null | RUXOLITINIB | 100570212 |
| 240002612 | 240005261 | 1.02 | 57 | Curative (C) | 2020-06-30 | 2020-06-30 | ALEMTUZUMAB + FLUDARABINE + LEAM | 02 | null | UKALL2011 | 100396553 |
| 240002613 | 240005262 | 0 | 82 | Adjuvant (A) | 2016-03-17 | 2016-03-24 | RUXOLITINIB | 01 | N | R-GEM-P | 101654756 |
| 240002615 | 240005263 | 1.67 | 102.8 | Disease modification (D) | 2019-04-21 | 2019-04-23 | null | 02 | null | AML INTERIM GUIDELINES FLAG-IDA | 100387847 |
| 240002616 | 240005264 | 1.69 | 75 | Curative (C) | 2018-05-06 | 2018-07-29 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | CISPLATIN + CYTARABINE + ETOPOSIDE | 100620403 |
| 240002617 | 240005265 | 1.67 | 110 | null | 2019-10-05 | 2019-11-02 | null | 02 | null | CISPLATIN + CYTARABINE + ETOPOSIDE | 100211687 |
| 240002618 | 240005266 | 1.83 | 91.6 | null | 2017-09-07 | 2017-09-08 | UKALL14- Intens/CNS Proph +Imatinib | 02 | N | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 100833068 |
| 240002619 | 240005267 | 0 | 17.3 | null | 2019-03-22 | 2019-04-01 | ALL UKALL2011 Ind A Std Dex (PAsp) | 02 | null | CLADRIBINE | 101456528 |
| 240002621 | 240005269 | 1.81 | 73.2 | Curative (C) | 2016-04-02 | 2016-04-02 | Cyclophosphamide + Etoposide (iv) | 02 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 101627133 |
| 240002623 | 240005270 | 1.84 | null | 03 | 2019-10-22 | 2020-01-20 | null | N | N | CHLORAMBUCIL + OBINUTUZUMAB | 101568772 |
| 240002625 | 240005272 | 1.72 | 87 | null | 2019-03-01 | 2019-03-07 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | null | METHOTREXATE INTRATHECAL | 101172769 |
| 240002626 | 240005273 | 1.67 | 28.05 | null | null | 2019-01-10 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | null | PEG INTERFERON | 100836511 |
| 240002627 | 240005274 | null | 68.8 | Palliative (P) | 2017-04-22 | 2017-04-22 | Methotrexate intrathecal | 02 | N | CYTARABINE INTRATHECAL | 100431545 |
| 240002628 | 240005275 | 1.75 | 56 | Curative (C) | null | 2018-05-24 | Midostaurin | N | null | AML MYECHILD 01 IT CYT | 100453163 |
| 240002629 | 240005276 | 1.61 | 65.4 | null | null | 2019-10-22 | Busulfan Oral | null | null | CHLORAMBUCIL + OBINUTUZUMAB | 100085960 |
| 240002630 | 240005277 | 1.6 | 94.6 | Palliative (P) | 2019-06-18 | 2019-06-25 | CODOX M | 02 | N | PEG INTERFERON | 100218318 |
| 240002631 | 240005278 | 0 | 30 | Curative (C) | 2015-10-05 | 2019-03-28 | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 02 | N | AML INTERIM GUIDELINES FLAG-IDA | 100610839 |
| 240002632 | 240005279 | 1.55 | 85.45 | Adjuvant (A) | 2016-03-11 | 2016-03-28 | Etoposide oral | 02 | N | AML MYECHILD 01 FLA | 100420743 |
| 240002633 | 240005280 | 1.8 | 62.5 | 03 | null | 2016-05-22 | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | null | N | RUXOLITINIB | 101429912 |
| 240002635 | 240005281 | null | null | null | null | 2019-12-14 | GEMTUZUMAB OZOGAMICIN | null | null | CAR-T AXICABTAGENE CILOLEUCEL + CYCLOPHOSPHAMIDE + FLUDARABINE | 100372850 |
| 240002636 | 240005282 | 1.82 | 24.3 | null | null | 2019-04-23 | RUXOLITINIB | null | null | ANAGRELIDE | 100642448 |
| 240002640 | 240005285 | 1.78 | 14 | null | null | 2018-11-12 | null | N | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100049936 |
| 240002642 | 240005287 | 1.67 | 19.8 | Palliative (P) | 2018-12-28 | 2018-12-30 | IVE-R | Y | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE | 100167709 |
| 240002643 | 240005288 | 1.67 | 87 | Curative (C) | 2018-03-16 | 2018-03-16 | Venetoclax | 02 | null | UKALL14- INTENS/CNS PROPH +IMATINIB | 100655920 |
| 240002646 | 240005291 | 1.65 | 9.95 | Curative (C) | 2020-01-23 | 2020-01-23 | CHOP - 21 days | 02 | N | AML DOWNS IT CYTARABINE | 100756652 |
| 240002647 | 240005292 | 1.63 | 60.8 | 03 | 2017-02-11 | 2017-02-14 | ABVD | 02 | N | FLAIR TRIAL | 101189509 |
| 240002649 | 240005293 | 1.79 | 133 | Curative (C) | 2017-03-01 | 2017-03-12 | Inotuzumab Ozogamicin | 02 | null | RUXOLITINIB | 101317489 |
| 240002650 | 240005294 | 1.7 | 67 | Curative (C) | 2017-06-07 | 2017-06-07 | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 02 | N | UKALL14- PH 2 INDUCTION | 101005314 |
| 240002651 | 240005295 | 1.69 | null | Curative (C) | 2017-08-27 | 2017-09-27 | null | 02 | null | IMATINIB | 100487371 |
| 240002652 | 240005296 | 1.76 | 15.4 | null | null | 2018-05-02 | GEMTUZUMAB OZOGAMICIN | 01 | N | ALL ALLR3: S/IR CONS | 100611346 |
| 240002653 | 240005297 | 0 | 83.1 | Disease modification (D) | 2019-10-29 | 2019-10-29 | Dasatinib | 02 | null | CYCLOPHOSPHAMIDE + RITUXIMAB | 100281202 |
| 240002655 | 240005299 | 0 | 28.1 | 03 | 2017-08-07 | 2017-08-07 | null | 02 | N | VENETOCLAX | 101646711 |
| 240002656 | 240005300 | 1.86 | 62.6 | null | 2018-11-10 | 2018-11-13 | AML MyeChild 01 FLA-Idarubicin | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100306061 |
| 240002657 | 240005301 | 1.84 | 11.9 | null | 2017-09-08 | 2017-09-08 | BUSULFAN + CYCLO | N | null | UKALL2011 | 100373006 |
| 240002658 | 240005302 | 0 | 49.6 | 03 | null | 2016-11-06 | Venetoclax | 01 | N | DA | 100599355 |
| 240002659 | 240005303 | 1.67 | 72 | Disease modification (D) | 2017-05-03 | 2017-09-26 | null | 02 | null | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 101341389 |
| 240002660 | 240005304 | 1.75 | 71.4 | Palliative (P) | 2018-02-13 | 2018-05-16 | FLAIR trial | 02 | null | IMATINIB | 101569313 |
| 240002664 | 240005308 | 1.63 | 55.9 | Curative (C) | 2016-09-26 | 2016-09-26 | null | 02 | null | ALL UKALL2011 AUG BFM CONS C | 101668404 |
| 240002665 | 240005309 | 1.77 | 71 | null | 2016-02-24 | 2016-03-12 | ALEMTUZUMAB + FLUDARABINE + LEAM | 02 | null | CYTARABINE HIGH DOSE | 101355122 |
| 240002666 | 240005310 | 1.45 | 73.7 | Curative (C) | 2019-04-25 | 2019-04-30 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | null | AML DOWNS HA | 101851747 |
| 240002667 | 240005311 | 1.56 | 0 | null | null | 2018-06-24 | null | 01 | null | CYTARABINE + DAUNORUBICIN | 100169468 |
| 240002668 | 240005312 | 1.63 | 64 | Palliative (P) | 2016-04-26 | 2016-04-26 | BENDAMUSTINE + CYTARABINE + RITUXIMAB | N | N | INTERFERON ALFA | 101535543 |
| 240002669 | 240005313 | 1.58 | 72.8 | null | 2016-11-10 | 2016-12-15 | DA-EPOCH-R | N | null | AML16 TRIAL | 100856222 |